Improving Cure Rates of B-Cell Acute Lymphoblastic Leukemia with Chimeric Antigen Receptor T Cells

Relevant prognostic factors vary across products and clinical settings. To improve cure rates, investigators are designing new CAR T products, using CAR T cells in earlier treatment settings, and focusing on addressing access barriers.

Authors

Yannis K. Valtis (ORCID: https://orcid.org/0000-0001-8927-8006)
Jae Hyun Park

Institutions

Memorial Sloan Kettering Cancer Center (US)

Publication Details

Journal: Acta Haematologica
Published: 2025-12-31
DOI: https://doi.org/10.1159/000550161
Primary Topic: CAR-T cell therapy research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Improving Cure Rates of B-Cell Acute Lymphoblastic Leukemia with Chimeric Antigen Receptor T Cells

Yannis K. Valtis, Jae Hyun Park

Dec 31, 2025

Acta Haematologica

CAR-T cell therapy research

article

Improving Cure Rates of B-Cell Acute Lymphoblastic Leukemia with Chimeric Antigen Receptor T Cells

Yannis K. Valtis, Jae Hyun Park

December 31, 2025article en

Abstract

Acta Haematologica

Memorial Sloan Kettering Cancer Center (US)

Good health and well-being

Openalex Percentile: Top 29%

CAR-T cell therapy research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Improving Cure Rates of B-Cell Acute Lymphoblastic Leukemia with Chimeric Antigen Receptor T Cells — Yannis K. Valtis, Jae Hyun Park · Acta Haematologica (2025) | TGRS Research Map | TGRS